AU2003291402A1 - MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE - Google Patents

MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Info

Publication number: AU2003291402A1
Authority: AU; Australia
Prior art keywords: 1alpha; mip; csf; adjuvants; immune response
Prior art date: 2002-11-07
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2003291402A

Other versions

AU2003291402A8 (en

Inventor

Dan Barouch

Norman Letvin

Paul Mckay

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Beth Israel Deaconess Medical Center Inc

Original Assignee

Beth Israel Deaconess Medical Center Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-07

Filing date

2003-11-07

Publication date

2004-06-03

2003-11-07 Application filed by Beth Israel Deaconess Medical Center Inc filed Critical Beth Israel Deaconess Medical Center Inc

2004-06-03 Publication of AU2003291402A8 publication Critical patent/AU2003291402A8/en

2004-06-03 Publication of AU2003291402A1 publication Critical patent/AU2003291402A1/en

Status Abandoned legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Mycology (AREA)
Epidemiology (AREA)
Immunology (AREA)
Medicinal Chemistry (AREA)
Microbiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU2003291402A 2002-11-07 2003-11-07 MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE Abandoned AU2003291402A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US42465802P	2002-11-07	2002-11-07
US60/424,658		2002-11-07
PCT/US2003/035693 WO2004044155A2 (en)	2002-11-07	2003-11-07	MIP-1α AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Publications (2)

Publication Number	Publication Date
AU2003291402A8 AU2003291402A8 (en)	2004-06-03
AU2003291402A1 true AU2003291402A1 (en)	2004-06-03

Family

ID=32312848

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2003291402A Abandoned AU2003291402A1 (en)	2002-11-07	2003-11-07	MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE

Country Status (2)

Country	Link
AU (1)	AU2003291402A1 (en)
WO (1)	WO2004044155A2 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7662781B2 (en) *	2005-01-31	2010-02-16	Eci, Inc.	Immunopotentiating agent
WO2009024426A1 (en) *	2007-07-27	2009-02-26	INSERM (Institut National de la Santé et de la Recherche Médicale)	Immunizing compositions for inducing 'bystander' killing of pathogens
SMT202000101T1 (en)	2008-10-10	2020-03-13	Childrens Medical Center	Biochemically stabilized hiv-1 env trimer vaccine
WO2012023631A1 (en) *	2010-08-19	2012-02-23	株式会社Eci	Pharmaceutical composition for inhibiting proliferation of cancer cells which comprises heat shock protein (hsp) and eci301 polypeptide, and cancer treatment method using same
AP2015008634A0 (en)	2013-01-07	2015-07-31	Beth Israel Hospital	Stabilized human immunodeficiency virus 'hiv' env elope 'env' trimer vaccines and methods of using same
US10376583B2 (en)	2013-09-30	2019-08-13	Beth Israel Deaconess Medical Center, Inc.	Human immunodeficiency virus therapies utilizing N332-glycan-dependent antibodies and a reservoir activator
US10716845B2 (en)	2013-10-04	2020-07-21	Beth Israel Deaconess Medical Center, Inc.	Stabilized human immunodeficiency virus (HIV) clade C envelope (Env) trimer vaccines and methods of using same
MY175620A (en)	2014-09-26	2020-07-02	Beth Israel Deaconess Medical Ct Inc	Methods and compositions for inducing protective immunity against human immunodeficiency virus infection
EP3964569A1 (en)	2015-12-15	2022-03-09	Janssen Vaccines & Prevention B.V.	Human immunodeficiency virus antigens, vectors, compositions, and methods of use thereof
KR102389489B1 (en)	2016-06-16	2022-04-22	얀센 백신스 앤드 프리벤션 비.브이.	HIV Vaccine Formulations
CA3035759A1 (en)	2016-09-02	2018-03-08	Janssen Vaccines & Prevention B.V.	Methods for inducing an immune response against human immunodeficiency virus infection in subjects undergoing antiretroviral treatment
SG11201901206SA (en)	2016-09-15	2019-04-29	Janssen Vaccines & Prevention Bv	Trimer stabilizing hiv envelope protein mutations
EP3526236B1 (en)	2016-10-17	2025-12-10	Beth Israel Deaconess Medical Center, Inc.	Signature-based human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
WO2018229711A1 (en)	2017-06-15	2018-12-20	Janssen Vaccines & Prevention B.V.	Poxvirus vectors encoding hiv antigens, and methods of use thereof
WO2019016062A1 (en)	2017-07-19	2019-01-24	Janssen Vaccines & Prevention B.V.	Trimer stabilizing hiv envelope protein mutations
US11845788B2 (en)	2018-05-22	2023-12-19	Beth Israel Deaconess Medical Center, Inc.	Antibody therapies for human immunodeficiency virus (HIV)
WO2020106713A1 (en)	2018-11-21	2020-05-28	Beth Israel Deaconess Medical Center, Inc.	Antibody therapies for human immunodeficiency virus (hiv)
WO2022182940A1 (en) *	2021-02-26	2022-09-01	The Feinstein Institutes For Medical Research	Neural control of adaptive immunity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5935568A (en) *	1995-05-18	1999-08-10	National Jewish Medical & Research Center	Gene therapy for effector cell regulation

2003
- 2003-11-07 AU AU2003291402A patent/AU2003291402A1/en not_active Abandoned
- 2003-11-07 WO PCT/US2003/035693 patent/WO2004044155A2/en not_active Ceased

Also Published As

Publication number	Publication date
WO2004044155A2 (en)	2004-05-27
AU2003291402A8 (en)	2004-06-03
WO2004044155A8 (en)	2004-08-19
WO2004044155A3 (en)	2005-10-06

Similar Documents

Publication	Publication Date	Title
AU2003291402A1 (en)	2004-06-03	MIP-1Alpha AND GM-CSF AS ADJUVANTS OF IMMUNE RESPONSE
AU2003258714A1 (en)	2004-03-29	Immune modulatory compounds and methods
WO2003072035A8 (en)	2005-07-28	Compositions and methods for the treatment of immune related diseases
WO2004041170A9 (en)	2010-01-21	Compositions and methods for the treatment of immune related diseases
WO2004024097A9 (en)	2010-01-21	Compositions and methods for the treatment of immune related diseases
AU2003259735A1 (en)	2004-02-25	Small-mer compositions and methods of use
ZA200602950B (en)	2007-09-26	Vaccine compositions comprising an interleukin 18 and saponin adjuvant system
AU2008243079A1 (en)	2008-11-27	Compositions and methods for generating an immune response
AU2002242085A1 (en)	2002-08-19	Methods and compositions useful for stimulating an immune response
WO2005025604A3 (en)	2005-06-09	Use of hmgb and hmgb fragments to decrease specific immune response
AU2003299823A1 (en)	2004-07-29	Methods of inducing and maintaining immune tolerance
AU2003217105A1 (en)	2003-09-16	Novel of cytokine inhibitors
AU2003270779A1 (en)	2004-04-08	Vaccine compositions and adjuvant
AU2003303926A1 (en)	2004-09-06	Ceramics and methods of making the same
AU2003259374A1 (en)	2004-03-19	Vaccine comprising il-13 and an adjuvant
WO2004024076A8 (en)	2005-09-01	Novel compositions and methods for the treatment of immune related diseases
AU2003245134A1 (en)	2004-01-06	Oxytocin as cardiomyogenesis inducer and uses thereof
AU2003302234A1 (en)	2004-06-18	Immune response associated proteins
AU2003260818A1 (en)	2004-06-18	Treatment of immune system dysfunction
AU2002338571A1 (en)	2002-11-11	Compositions and methods for suppressing immune responses
AU2002361488A1 (en)	2004-07-22	Field and background of the invention
AU2003239773A1 (en)	2004-01-19	Preparation of vaccines
AU2003268230A1 (en)	2004-03-19	Immune response associated proteins
AU2003212475A1 (en)	2003-09-16	Immune response associated proteins
AU2002240013A1 (en)	2002-08-06	Chemokines as adjuvants of immune response

Legal Events

Date	Code	Title	Description
2005-07-21	MK6	Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase